Stereotaxis Inc (STXS)vsWest Pharmaceutical Services Inc (WST)
STXS
Stereotaxis Inc
$1.88
+4.17%
HEALTHCARE · Cap: $174.08M
WST
West Pharmaceutical Services Inc
$247.02
+0.71%
HEALTHCARE · Cap: $17.68B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 9395% more annual revenue ($3.07B vs $32.38M). WST leads profitability with a 16.1% profit margin vs -66.8%. STXS appears more attractively valued with a PEG of 1.31. WST earns a higher WallStSmart Score of 55/100 (C-).
STXS
Avoid34
out of 100
Grade: F
WST
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for STXS.
Margin of Safety
-256.8%
Fair Value
$68.99
Current Price
$247.02
$178.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 36.3% year-over-year
Safe zone — low bankruptcy risk
Strong operational efficiency at 21.6%
Areas to Watch
Trading at 13.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -143.6% — below average capital efficiency
Premium valuation, high expectations priced in
2.1% earnings growth
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : STXS
The strongest argument for STXS centers on Revenue Growth. Revenue growth of 36.3% demonstrates continued momentum. PEG of 1.31 suggests the stock is reasonably priced for its growth.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.
Bear Case : STXS
The primary concerns for STXS are Price/Book, EPS Growth, Market Cap.
Bear Case : WST
The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.
Key Dynamics to Monitor
STXS profiles as a hypergrowth stock while WST is a mature play — different risk/reward profiles.
STXS carries more volatility with a beta of 1.40 — expect wider price swings.
STXS is growing revenue faster at 36.3% — sustainability is the question.
WST generates stronger free cash flow (175M), providing more financial flexibility.
Bottom Line
WST scores higher overall (55/100 vs 34/100), backed by strong 16.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Stereotaxis Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (MRI) systems for use in the hospital's interventional operating room to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. The company is headquartered in St. Louis, Missouri.
West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?